Skip to main content

FABP5 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 22 bp deletion in exon 2 and 2 bp deletion in exon 2.

Be the first to review this product! Submit a review

Images

Western blot - Human FABP5 knockout HeLa cell line (AB265905), expandable thumbnail
  • Western blot - Human FABP5 knockout HeLa cell line (AB265905), expandable thumbnail
  • Sanger Sequencing - Human FABP5 knockout HeLa cell line (AB265905), expandable thumbnail
  • Sanger Sequencing - Human FABP5 knockout HeLa cell line (AB265905), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, 22 bp deletion in exon 2 and 2 bp deletion in exon 2

Alternative names

CFABP, Cutaneous fatty acid binding protein, DA11, Differentiation associated lipid binding protein LP2, E-FABP, Epidermal-type fatty acid-binding protein, FABP5_HUMAN, Fatty acid binding protein epidermal, Fatty acid-binding protein 5, KFABP, Keratinocyte lipid binding protein, Klbp, PA-FABP, Psoriasis-associated fatty acid-binding protein homolog, fatty acid binding protein 5 (psoriasis-associated)

Recommended products

FABP5 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 22 bp deletion in exon 2 and 2 bp deletion in exon 2.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, 22 bp deletion in exon 2 and 2 bp deletion in exon 2
Antibiotic resistance
Puromycin 1µg/mL
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
FABP5
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (Human wild-type HeLa cell line ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

The FABP5 protein also known as Fatty Acid Binding Protein 5 or Epidermal-type Fatty Acid Binding Protein (E-FABP) serves an important role in the transport and metabolism of long-chain fatty acids. It has a molecular mass of approximately 15 kDa. FABP5 is expressed in multiple tissues with notably high expression in the epidermis brain liver and adipose tissue. This protein assists in intracellular fatty acid movement affecting cellular lipid catabolism.

Biological function summary

FABP5 interacts with specific ligands such as long-chain fatty acids which influences cellular processes like growth differentiation and energy homeostasis. It is not known to be part of a larger complex. This protein is integral in regulating lipid signaling pathways and responses due to its binding capacity which modulates the availability of fatty acids for metabolic processes. Its expression pattern hints at a possible role in the body's adaptation to dietary lipid intake.

Pathways

FABP5 holds a significant position in the peroxisome proliferator-activated receptor (PPAR) signaling pathway and the fatty acid metabolism pathway. In the PPAR signaling pathway FABP5 influences the activity of PPARβ/δ receptors which regulate gene expression involved in lipid metabolism and energy homeostasis. It is related to other fatty acid binding proteins such as FABP4 which similarly participate in lipid metabolic processes and have roles in the regulation of lipid and glucose metabolism.

Associated diseases and disorders

Researchers have linked FABP5 to conditions like psoriasis and type 2 diabetes. In psoriasis the overexpression of FABP5 has been observed in skin lesions suggesting that it might contribute to the pathological process. FABP5 is also connected to metabolic syndrome and insulin resistance as its dysregulation can influence lipid and glucose metabolism processes. In these disorders FABP5 interacts with proteins like PPARγ indicating possible intervention points for therapeutic targeting.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

4 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com